Post-Renal Transplantation Dyslipidemia.
- Author:
Jaeseok YANG
1
;
Curie AHN
Author Information
1. Department of Internal Medicine, College of Medicine, Seoul National University, Seoul, Korea. curie@plaza.snu.ac.kr
- Publication Type:Review
- Keywords:
Dyslipidemia;
Renal transplantation;
Ischmic heart disease;
Chronic allograft dysfunction
- MeSH:
Allografts;
Cardiovascular Diseases;
Dyslipidemias*;
Epidemiology;
Graft Survival;
Humans;
Immunosuppressive Agents;
Kidney Transplantation;
Myocardial Ischemia;
Quality of Life;
Risk Factors;
Survivors
- From:The Journal of the Korean Society for Transplantation
2004;18(1):1-12
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Long-term survivors in renal transplantation have been increasing, as medical care has improved in addition to development of new immunosuppressants. Therefore, cardiovascular disease, especially ischemic heart disease and chronic allograft dysfunction have become main obstacles to longer survival and better quality of life. Dyslipidemia, which is a well-known risk factor of ischemic heart disease in general population, is more common in renal transplantation patients. Moreover, dyslipidemia is suggested as a nonimmunological risk factor of chronic allograft dysfunction. Therefore, it is important to manage dyslipidemia properly to improve patient and graft survival in renal transplantation. But, specific approach, tailored to renal transplant patients is necessary in the treatment of dyslipidemia, because there are significant differences between renal transplantation patients and general population. We present here, epidemiology, mechanism, and impact of dyslipidemia on ischemic heart disease and chronic allograft dysfunction, and overall approach to dyslipidemia in renal transplantation patients, including treatment guideline.
